ResultsIQ

ResultsIQ › Latest results › Sai Parenterals Limited

Sai Parenterals Limited Q2 FY27 earnings call summary

NSE: SAIPARENT · BSE: 544742

Earnings call of 2 Nov 2026, summarised by AI from the filing.

Sai Parenterals Q2 FY27 EBITDA rose to ₹41.4 cr at 21.1% margin on revenue of ₹196.1 cr, with FY27 revenue target of ₹750 cr reiterated.

Key takeaways

  1. FY27 guidance Management expects to comfortably cross the ₹750 cr FY27 revenue target and keep EBITDA margin above 17%.
  2. Gross margin Gross margin rose to 47.5% from 40.9% on tighter inventory management and lower raw material cost.
  3. Adelaide Adelaide commissioning expected January 2027, moving outsourced volumes in-house and converting distribution margin to manufacturing margin.
  4. Execution risk Adelaide commissioning slipped to January 2027 from earlier advice due to logistics disruptions from the Iran conflict.

Original filing on BSE

Sai Parenterals Limited Q2 FY27 results

As filed: Revenue ₹195 cr, EBITDA ₹40.2 cr, PAT ₹10.5 cr, EBITDA margin 20.6%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹195 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹179 cr, EBITDA ₹23.5 cr, PAT ₹7.9 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹179 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.9% in 30 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹198 cr, EBITDA ₹26.1 cr, PAT ₹13.2 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹198 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +20.8% in 30 days (Nifty 500: +2.7%).
  • Q3 FY26: Revenue ₹96.2 cr, EBITDA −₹3.6 cr, PAT −₹6.7 cr, EBITDA margin -3.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹96.2 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Parenterals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.